Communicate with Supplier? Supplier
Vicky Ms. Vicky
What can I do for you?
Chat Now
Chat Now Contact Supplier
Jinan Guoding Pharmaceutical Co.,Ltd
About Us
Jinan Guoding Pharmaceutical Co., Ltd. is a high-tech company specialized in R & D, production, operation and sales of pharmaceutical intermediates and API products. We provides services such as technology development, technology transfer technical services. and also provides high quality products, based on the principle of "quality first, integrity essential, customer service, and technological innovation", with innovation driven as the core, quality management as the guarantee, the company is aggressive and innovative, and is committed to providing customers with high-quality products and professional services.
View more Visit My Factory
Product Center
Larotrectinib IntermediatesEntrectinib IntermediatesRepotrectinib IntermediatesBrigatinib IntermediatesIbrutinib Intermediates
Latest News

Focus on the latest news of the company and industry, and keep abreast of the latest developments

  • Amenamevir is a potent helicase–primase inhibitor and a novel class of antiviral agent other than nucleoside compounds, such as aciclovir, valaciclovir and famciclovir. This study is the first randomized, double‐blind, valaciclovir‐controlled phase 3 study to evaluate the efficacy and safety of amenamevir in Japanese patients with herpes zoster when treated within 72 h after onset of rash. A total of 751 patients were randomly assigned to receive either amenamevir 400 mg or 200 mg p.o. once daily or valaciclovir 1000 mg three times daily (daily dose, 3000 mg) for 7 days. The primary efficacy end‐point was the proportion of cessation of new lesion formation by day 4 ([day 4 cessation proportion"). The day 4 cessation proportions for amenamevir 400 and 200 mg and valaciclovir were 81.1% (197/243), 69.6% (172/247) and 75.1% (184/245), respectively. Non‐inferiority of amenamevir 400 mg to valaciclovir was confirmed by a closed testing procedure. Days to cessation of new lesion formation, complete crusting, healing, pain resolution and virus disappearance were evaluated as secondary end‐points. No significant differences were observed in any of the treatment groups. Amenamevir 400 and 200 mg were well tolerated as well as valaciclovir. The proportions of patients who experienced drug‐related adverse events were 10.0% (25/249), 10.7% (27/252) and 12.0% (30/249) with amenamevir 400 and 200 mg and valaciclovir, respectively. In conclusion, amenamevir 400 mg appears to be effective and well tolerated for treatment of herpes zoster in immunocompetent Japanese patients. Jinan guoding Pharmaceutical Co.,Ltd,a manufacturer of Amenamevir Intermediates, mainly three Intermediates. 1).2H-Thiopyran-4-ca
  • Looking at the pipeline for larotrectinib, it shows an accelerated course, which can be attributed to the drug`s potential to fulfill an unmet need in oncology. Following larotrectinib`s discovery in 2013, in in vitro models, the agent demonstrated high potency against TRKA, TRKB, and TRKC, which are 3 TRK proteins that are encoded by NTRK1, NTRK2, and NTRK3. In solid tumors, the agent was preclinically tested on a lung adenocarcinoma cell line harboring an MPRIP–NTRK1 fusion, as well as a colorectal cancer cell line harboring a TPM3-NTRK1 fusion.Larotrectinib also had preclinical evaluation in hematologic malignancies in an acute myeloid leukemia cell line harboring an ETV6
  • Praprofen eye drops is a propionic acid non-steroidal anti-inflammatory drug Praprofen eye drops. Its action mechanism is to reduce the biosynthesis of prostaglandins by inhibiting cyclooxygenase activity in the body. Department of symptomatic treatment. It has been reported in the literature that beta-cyclodextrin can enhance the stability of eye drops, but unmodified beta-cyclodextrin cannot meet the application requirements in terms of solubility, hemolysis, and toxicity. As a derivative of beta-cyclodextrin, Betadex Sulfobutyl Ether Sodium has the advantages of good water solubility, small hemolytic effect, and low renal toxicity, and can provide solubility and stability of the drug. With the addition of Betadex Sulfobutyl Ether Sodium, the irritation of the eyes of Praprafen eye drops is significantly reduced, the stability is also significantly improved, and its bioavailability is also improved.
Featured Products



Recommend our products for you, so that you can quickly preview the products.

View more
  • High quality with 1363380-51-1 Larotrectinib Intermediates
  • Larotrectinib Intermediates CAS  1919868-77-1
  • Intermediates of Alectinib CAS 1256584-73-2
  • Intermediates of Repotrectinib CAS 1224944-77-7
  • High quality CAS 1108745-30-7 Entrectinib Intermediates
  • BOC-1-Amino-1-cyclopropanecarboxylic acid   CAS 88950-64-5
  • Intermediates of Entrectinib  CAS 1108745-25-0
  • Larotrectinib Intermediates   CAS:33884-43-4
  • CAS:1223404-88-3   LOXO-101 Intermediates
  • Intermediates of Entrectinib CAS 1034975-62-6
Related Products List




About Us